Skip to main content
OpenTrials

Clinical trial condition

Neoplasms, Plasma Cell

Explore clinical trials studying Neoplasms, Plasma Cell. Study availability and eligibility vary by location and protocol.

2,599 public trials 548 recruiting studies
Refine in advanced search Browse all conditions

Neoplasms, Plasma Cell trial results

Active, Not Recruiting

A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

NCT03314181

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Univ of Colorado Cancer Center /ID# 167331 Aurora, Colorado, United States
  • Moffitt Cancer Center /ID# 169614 Tampa, Florida, United States
  • Winship Cancer Institute of Emory University /ID# 165427 Atlanta, Georgia, United States
  • The University of Chicago Medical Center /ID# 165429 Chicago, Illinois, United States
View all 40 locations
View Trial Details
Active, Not Recruiting

A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets

NCT05308654

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Stanford University School of Med /ID# 242809 Stanford, California, United States
  • Sylvester Comprehensive Cancer Center /ID# 243417 Miami, Florida, United States
  • Tulane University School of Medicine /ID# 244854 New Orleans, Louisiana, United States
  • American Oncology Partners of Maryland /ID# 244858 Bethesda, Maryland, United States
View all 21 locations
View Trial Details
Active, Not Recruiting

A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan

NCT05286229

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • National Cancer Center Hospital East /ID# 240943 Kashiwa-shi, Chiba, Japan
  • Hokkaido University Hospital /ID# 242672 Sapporo, Hokkaido, Japan
  • Kanazawa University Hospital /ID# 240948 Kanazawa, Ishikawa-ken, Japan
  • Duplicate_Okayama Medical Center /ID# 240949 Okayama, Okayama-ken, Japan
View Trial Details
Active, Not Recruiting

Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib

NCT04790474

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Emek Medical Center Afula, Israel
  • Rambam Medical Center Haifa, Israel
  • Hadassah Ein-Kerem Medical Center Jerusalem, Israel
  • Shearei Zedek Medical Center Jerusalem, Israel
View Trial Details
Active, Not Recruiting

Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma

NCT05123131

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Aarhus University Hospital Aarhus, Denmark
  • Beaumont Hospital Dublin, Ireland
  • Mater Misericordiae University Hospital Dublin, Ireland
  • St James's Hospital Dublin, Ireland
View Trial Details

Related conditions